Interleukin 4 Expressed In Situ Selectively Alters Thymocyte Development

By David B. Lewis,* Charles C. Yu,* Katherine A. Forbush,†
Joan Carpenter§, Timothy A. Sato,‖ Angelika Grossman,§
Denny H. Liggitt,§ and Roger M. Perlmutter‡

From the Departments of *Pediatrics, †Immunology, §Comparative Medicine, and the ‡Howard Hughes Medical Institute, University of Washington, Seattle, Washington 98195; and the ‖Department of Immunology, Immunex Corporation, Seattle, Washington 98101

Summary

Using a transgenic mouse model we show that increased intrathymic expression of interleukin 4 (IL4) significantly perturbs the development of thymocytes. Transgenic double-positive (CD4+CD8+) thymocytes, which are present in dramatically reduced numbers, exhibit increased T cell receptor (TCR) expression and increased mobilization of calcium mediated by these receptors. In contrast, transgenic single-positive (CD4+CD8- and CD4-CD8+) thymocytes and peripheral T cells exhibit decreased TCR-mediated calcium mobilization. The development of CD4-CD8+ thymocytes is significantly perturbed by IL-4 expressed in vivo; only peripheral CD4+ T cells are found in significant numbers in transgenic mice, while CD4-CD8+ thymocytes are present in increased numbers, apparently because of their failure to emigrate to the periphery. In contrast to these selective effects on T cell development, no significant differences in the numbers of B cells or mast cells, or in the plasma levels of IgE and IgG1 are observed between transgenic and control mice. These observations suggest that IL-4 in vivo exerts its major effects locally rather than systemically, even when its expression is constitutively increased.

IL-4 is a cytokine secreted by T cells and mast cells which has pleotropic effects on a wide variety of hematopoietic cell types in vitro (1). Originally described as a growth factor for partially activated B cells (2), IL-4 has subsequently been shown to promote T cell and mast cell growth as well (3–5), and to have multiple effects on the differentiation of mature lymphocytes (1, 6–10). These IL-4-mediated effects include increased class II MHC surface expression and IgG1 and IgE production by B cells (6–8), enhanced generation of T cell-mediated cytotoxicity (9), and the induction of surface CD8 expression by CD4+ T cell clones (10). Although these findings suggest that IL-4 regulates multiple aspects of antigen-specific immunity, the production of IgE by B-lineage cells is the only lymphocyte-mediated function which has clearly been shown to depend on the production of IL-4 in vivo (11, 12).

The expression of IL-4 mRNA by thymocytes in vivo during fetal ontogeny (13), and the secretion of IL-4 by fetal and adult CD4+CD8- (double-negative) thymocytes after in vitro activation (14, 15), suggest that this cytokine may also have a role in normal T cell development. A number of in vitro studies have documented that IL-4 can either augment or inhibit the growth of isolated thymocytes, depending on the cell population studied, the stimulus used for cell activation, and which other cytokines are present (15–20). Studies of CD4−CD8- thymocyte differentiation in vitro indicate that IL-4 may favor the development of double-negative or CD8- cells bearing γ/δ rather than α/β T cell receptors (16, 21). However, these studies do not satisfactorily address the function of IL-4 in an intact intrathymic context; it is likely that IL-4 and other cytokines significantly influence other components of the thymic microenvironment which provide essential signals regulating thymocyte growth, differentiation, and selection. Therefore, we have generated transgenic mice in which IL-4 is selectively expressed intrathymically. Such animals exhibit profound but selective disturbances in thymocyte development, including an accumulation of thymocytes bearing high levels of TCR-α/β and a CD4-CD8+ surface phenotype. Remarkably, intrathymic IL-4 expression does not alter the normal pattern of Ig isotypes in plasma or B cell or mast cell abundance. These results suggest that IL-4 can behave as a natural regulator of thymocyte maturation, but that its effects are exerted locally rather than systemically.

Materials and Methods

Preparation of the Lck-IL4 Construct. The Lck-IL4 construct (Fig. 1) was made by inserting a full-length murine IL-4 cDNA clone,
Abbreviations used in this paper: [Ca\textsuperscript{2+}]i, intracellular calcium concentration; hGH, human growth hormone.

Generation of lck-\textit{IL-4} Transgenic Mice. A 0.6-kb Noto fragment containing the lck-\textit{IL-4} construct was purified by agarose gel electrophoresis onto DEAE-nitrocellulose paper (23) and diluted to 2 ng/ml in 10 mM Tris, 0.1 mM EDTA, pH 7.5. Aliquots of this preparation were injected into the pronuclei of C57BL/6 J X DBA/2 F\textsubscript{2} hybrid mouse zygotes using standard techniques (27). Viable zygotes were then transferred into the oviducts of recipient pseudo-pregnant females. Mice bearing the construct were detected by hybridization of blotted tail DNA as previously described (25), using a 32P-labeled 0.6-kb BamH1-EcoRI fragment of the human growth hormone (hGH)\textsuperscript{1} gene (26). The IL-4 cDNA was the generous gift of Dr. E. Severinson (University of Stockholm, Stockholm, Sweden).

Cell Isolation and Stimulation. Single-cell suspensions of thymocytes and LN cells were prepared by briefly mincing or teasing tissues. To isolate spleen mononuclear cells, tissue was first disrupted with a fine-meshed sieve, and the mononuclear cell fraction was subsequently purified by Ficoll-Hypaque density gradient centrifugation (31). Bone marrow cells were collected by irrigation of femurs with a fine-meshed sieve, and the mononuclear cell fraction was subsequently purified by Ficoll-Hypaque density gradient centrifugation (32). Bone marrow cells were collected by irrigation of femurs and humeri from euthanized mice (33). As necessary, contaminating red cells were removed by hypotonic NH\textsubscript{4}Cl treatment (33).

IL-4 Assay. Thymocytes, splenocytes, or bone marrow cells (5 \times 10\textsuperscript{6} /ml) from transgenic mice or control littermates were cultured in CT.45 medium (34) (RPMI 1640 [Mediatech, Washington, DC] with 10% FCS [Hyclone Laboratories, Logan, UT]), 1 mM Na pyruvate, 2 mM l-glutamine, 0.05 mM 2-ME, 100 U/ml penicillin, and 100 µg/ml streptomycin for 24 h at 37°C in a humidified 5% CO\textsubscript{2} atmosphere. IL-4 activity was determined by the ability of supernatants from these cell cultures to support the incorporation of [3H]thymidine by CT4S cells (the kind gift of WE. Paul, National Institutes of Health [NIH], Bethesda, MD), exactly as previously described (34). The concentration of IL-4 in samples was interpolated from a standard curve generated using purified recombinant murine IL-4. Based on this standard curve, the lower limit of detectability for IL-4 in the CT.45 assay was 10 pg/ml. An aliquot of each sample was preincubated with saturating concentrations (75 µg/ml) of purified 11B11 (anti-murine IL-4) mAb (35) for 45 min at 4°C before their addition to CT4S cells, to confirm that [3H]thymidine incorporation was IL-4 dependent. Purified recombinant murine IL-4 and 11B11 mAb were provided by Dr. K. Grabstein (Immunex Corp., Seattle, WA).

Immuno fluorescent Flow Cytometry. The following preparations of anti-murine mAbs were used for flow cytometric analysis: 500A.2 (reference 36) (CD3) hybridoma supernatant; FITC-conjugated 145-2C11 (reference 37) (CD3); biotinylated H57-597 (reference 38) (pan-\textalpha/\textbeta TCR); PE-conjugated GK1.5 (reference 39) (CD4); biotinylated and FITC-conjugated 53-6.7 (reference 40) (CD8). 500A.2 was kindly provided by Dr. J. Allison (University of California, Berkeley, CA). 145-2C11 and H57-597 were gifts of Dr. A. Farr (University of Washington, Seattle, WA). Biotinylated 53-6.7 was generously provided by Dr. B. J. Fowles (NIH). The remaining mAbs were purchased from Becton Dickinson (Mountain View, CA). Single or two-color staining of cells was performed at 4°C in PBS/1% BSA/0.1% Na azide (staining buffer) with saturating concentrations of mAb as previously described (41). PE-conjugated streptavidin (Biomedica, Foster City, CA) was used for detection of biotinylated mAb. For single or two-color analysis, at least 3 \times 10\textsuperscript{5} lymphocytes per sample were analyzed using an Epics C instrument (Coulter Electronics Inc., Hialeah, FL) equipped with an argon laser. For three-color staining of CD3, CD4, and CD8, cells in staining buffer were sequentially incubated for 15 min at 4°C with 500A.2 hybridoma supernatant, FITC-conjugated goat anti-hamster IgG (mouse and rat IgG absorbed) (Caltag Laboratories, South San Francisco, CA), 10% normal rat serum, biotinylated 53-6.7, streptavidin–allophycocyanin (Biomedica), and PE-conjugated GK1.5. Cells were extensively washed between each step. Three-color analysis was performed on an Epics 753 instrument (Coulter Electronics Inc.) using argon and helium-neon lasers. At least 1 \times 10\textsuperscript{5} list mode–gated events were collected per sample. Data was analyzed using MDADS and REPROF software (Fred Hutchinson Cancer Research Center, Seattle, WA).

In Vivo Treatment with Anti-IL-4 mAb. Starting at 1 mo of age, transgenic mice or littermate controls were given three weekly injections by tail vein of either 10 µg of purified anti-IL-4 11B11 mAb (35) in 0.25–0.5 ml of PBS (pH 7.4) or PBS alone. Mice were sacrificed for analysis 1 wk after their final injection.

Ca\textsuperscript{2+} Analy sis. Cells (10\textsuperscript{7}/ml in RPMI medium with 10% FCS) were loaded with 3 µg/ml of the acetoxyethyl ester of indo-1 (42) for 45 min at 37°C in darkness, washed, and then stained with saturating concentration of azide-free PE-conjugated CD4 and FITC-conjugated CD8 mAb (Becton Dickinson). After additional washing, cells were resuspended at 5 \times 10\textsuperscript{6} /ml in RPMI medium. Cytoplasmic free (intracellular) calcium concentration ([Ca\textsuperscript{2+}]i) was measured in individual cells by cytofluorometrically determining their ratio of violet to blue emissions as previously described (43); PE and FITC fluorescence were also simultaneously determined. Measurements were performed at 37°C at a rate of \sim 1,000 cells/s using a Cytofluorograph 50H with a model 2150 computer (Ortho Diagnostic Systems, Westwood, MA) as previously described (43, 44). When baseline [Ca\textsuperscript{2+}]i was established, cells were resuspended at 5 \times 10\textsuperscript{6} /ml, respectively, and flow was resumed. Computer analysis for [Ca\textsuperscript{2+}]i vs. time and percent-responding cells vs. time was performed as previously described (44) using the software Multitime (Phoenix Flow Systems, San Diego, CA).

Cell Activation. Round-bottom 96-well microtiter plates (Corning Glass Works, Corning, NY) were incubated with either mAb 145-2C11 (37) (10 µg/ml in PBS), mAb H57-597 (38) (1:10,000 dilution (vol/vol) of ascites in PBS, provided by Dr. J. Ledbetter (Oncogene, Seattle, WA), or with PBS alone for 2 h at 37°C and
then washed five times with PBS. Spleen mononuclear cells \((4 \times 10^4 - 2 \times 10^6)\) were added to wells in 0.2 ml of CT4S medium and incubated for 72 h at 37°C in a humidified atmosphere with 5% CO2. All wells were pulsed for the last 12 h of incubation with 1 \(\mu\)Ci of \[^{3}H\]thymidine. Cells were harvested onto glass fiber filters and assayed for \[^{3}H\]thymidine incorporation by liquid scintillation counting. All assays were performed in triplicate.

**Ig Isotype Analysis.** Ig levels were determined by an isotype-specific sandwich ELISA technique. The assays for IgG1, IgG3, and IgE levels were performed as previously described (45). IgG2a, IgG2b, IgA, and IgM levels were similarly determined using appropriate isotype-specific goat anti-mouse antibodies (Southern Biotechnology Associates, Birmingham, AL) as first-step reagents to coat the wells of microtiter plates. After blocking with 5% nonfat dry milk, wells were incubated with plasma or isotype standards (Southern Biotechnology Associates) diluted in PBS/3% BSA for 1 h, washed six times with PBS/0.5% Tween (Sigma Chemical Co., St. Louis, MO), and then incubated with appropriate isotype-specific, horseradish peroxidase-conjugated, goat anti-mouse antibodies (Southern Biotechnology Associates) for 1 h. After six washes with PBS/0.5% Tween, peroxidase-conjugated antibody was detected using TMB Microwell peroxidase substrate (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) as specified by the manufacturer. Plates were read on an ELISA reader (Dynatech Laboratories, Inc., Alexandria, VA). Data analysis of test samples was performed as previously described (45).

**Results**

**Selective Intrathymic Expression of IL-4 in lck-IL4 Transgenic Mice.** To gain insight into the potential role of IL-4 in T-lineage cell development in vivo, transgenic mice were generated in which increased IL-4 expression was selectively targeted to the thymus. Fig. 1 details the transgene expression construct \((lck-IL4)\) in which a 3.2-kb lck proximal promoter segment (24, 25) was placed immediately 5' to a full-length murine IL4 cDNA clone. The lck proximal promoter has previously been shown to direct the expression of other transgenes in a thymocyte-specific manner (24) and Perlmutter, R. M., unpublished results). The IL4 cDNA segment was embedded within the hGH gene since intronic sequences appear to augment transgene expression (46). By positioning the cDNA 5' to the translation initiation codon of the hGH gene, no growth hormone expression is observed (data not shown).

Three transgene-positive mice that expressed detectable transgene-derived mRNA were obtained after injection of the lck-IL4 construct. These founder animals, designated 1315, 4453, and 4475 displayed a distinct perturbation of T-lineage cell development that included \(a\) thymic hypoplasia; \(b\) a marked decrease in the number of CD4+CD8+ thymocytes; \(c\) an absolute increase in the number of CD4-CD8+ thymocytes; \(d\) a decreased number of peripheral CD4+ T cells; and \(e\) the virtual absence of peripheral CD8+ T cells. The estimated number of copies of the transgene in the 1315, 4453, and 4475 founders was 8, 5, and 5, respectively, based on densitometry of tail DNA blots hybridized with an IL4 cDNA probe (data not shown). Since the transgene copy number and the degree of perturbation of T-lineage cells in these three founders were similar, this indicated that the particular integration site of the transgene did not have a significant influence on the phenotype we observed. Described below, in detail, are the results obtained with the 1315 founder and six generations of its progeny.

Tissue expression of the lck-IL4 transgene was determined by hybridization of RNA blots with an IL4 cDNA probe (Fig. 2). Transgene-encoded IL4 transcripts, which contain 3' hGH sequences (Fig. 1), were significantly larger and readily distinguished from the endogenous 0.7-kb IL4 transcripts found in EL-4 cells. Two major sizes of transgenic IL4 mRNA were observed, presumably because of alternative splicing of hGH intron sequences. Low levels of transgene transcripts were detected in spleen (\(\sim 1-2\%\) of that found in thymocytes based on scanning densitometry) as well as LN tissue.
Table 1. IL-4 Secretion (pg/ml) by Unstimulated Cells from lck-IL-4 and Littermate Control Mice

| Cell Type                  | 11B11 mAb | 11B11 mAb |
|----------------------------|-----------|-----------|
| Exp. 1: 6-wk-old mice      |           |           |
| lck-IL-4 thymocytes        | 29        | <10       |
| LM control thymocytes      | <10       | ND        |
| lck-IL-4 splenocytes       | <10       | <10       |
| LM control thymocytes      | <10       | ND        |
| lck-IL-4 bone marrow cells | <10       | <10       |
| LM control bone marrow cells| <10       | ND        |
| Exp. 2: 9-wk-old mice      |           |           |
| lck-IL-4 thymocytes        | 69        | <10       |
| lck-IL-4 thymocytes        | 44        | <10       |
| LM control thymocytes      | <10       | ND        |
| Exp. 3: 18-d gestation embryo |   |           |
| lck-IL-4 thymocytes        | 28        | <10       |
| LM control thymocytes      | <10       | <10       |

(data not shown), but not in nonlymphoid tissues. Endogenous IL-4 transcripts were undetectable in RNA from all freshly isolated tissues of transgenic as well as littermate control mice (Fig. 2, data not shown). Taken together, these results demonstrated that lck-IL-4 mice had increased expression of IL-4 mRNA which was largely confined to the thymus.

The CT.4S cell proliferation assay (34) was used to measure the amount of biologically active IL-4 secreted by transgenic or control cells after short-term in vitro culture. Increased expression of IL-4 mRNA by thymic tissue in lck-IL-4 mice was paralleled by IL-4 secretion by thymocytes beginning as early as day 18 of fetal life (Table 1). Anti-IL-4 mAb completely neutralized this proliferative activity in the CT.4S assay, confirming that it was attributable to IL-4. The amount of IL-4 secreted by unstimulated thymocytes over a 24-h period ranged from ~25 to 70 pg/ml based on the activity of purified rIL-4 in the CT.4S assay. In contrast, IL-4 was not detected in cultures of control thymocytes, or in cultures of splenocytes or bone marrow cells from either transgenic or control mice.

Perturbation of Thymocyte Development. The amount of thymic tissue in lck-IL-4 mice was markedly reduced compared with controls, with the loss of a clearly defined cortical region (Table 2, Fig. 3 A and B). In virtually the entire organ, thymocytes were found in a loosely packed pattern characteristic of the normal medulla (Fig. 3 C and D). This reduction in thymocyte number compared with controls was evident as early as day 3 after birth but not at day 16.5 of fetal gestation (data not shown). Consistent with these findings, the proportion and absolute number of CD4+CD8+ cells, a population which normally includes >75% of thymocytes and is found mainly in the cortex (47), were both markedly lower in transgenic compared with control mice (Fig. 4 A, Table 2). This decrease was accompanied by an increased proportion of CD4+CD8- , CD4-CD8- , and, particularly, CD4+CD8- thymocytes. The CD4+CD8+ / CD4+CD8- thymocyte ratio in lck-IL-4 mice was typically greater than 1:1, and the absolute numbers of CD4+CD8+ cells exceeded those found in controls (Table 2). A significant proportion of CD4+CD8- and CD4-CD8+ lck-IL-4 thymocytes were also noted to have moderately reduced surface expression of CD4 or CD8, respectively, compared with thymocytes from controls (Fig. 4 A).

Table 2. Abundance of Thymocytes and Thymocyte Subpopulations in lck-IL-4 and Littermate Control Mice

| Surface phenotype (% of cells) | thymocytes | CD4- CD8- | CD4+CD8- | CD4-CD8+ | CD4+CD8+ |
|-------------------------------|------------|-----------|-----------|-----------|-----------|
| Exp. 1: 3-wk-old mice         | × 10⁶      |           |           |           |           |
| lck-IL-4                      | 29         | 8 (2)*    | 25 (7)    | 42 (12)   | 25 (7)    |
| lck-IL-4                      | 31         | 10 (3)    | 25 (9)    | 46 (14)   | 19 (6)    |
| LM control                    | 151        | 4 (6)     | 11 (17)   | 4 (6)     | 81 (122)  |
| LM control                    | 139        | 7 (10)    | 15 (21)   | 7 (10)    | 71 (99)   |
| Exp. 2: 9-wk-old mice         |           |           |           |           |           |
| lck-IL-4, PBS treated         | 28         | 9 (3)     | 28 (8)    | 33 (9)    | 30 (8)    |
| lck-IL-4, 11B11 treated       | 126        | 11 (14)   | 24 (30)   | 13 (16)   | 53 (67)   |
| lck-IL-4, 11B11 treated       | 110        | 9 (10)    | 24 (26)   | 12 (13)   | 55 (60)   |
| LM control, PBS treated       | 106        | 4 (4)     | 8 (8)     | 3 (3)     | 85 (90)   |
| LM control, 11B11 treated     | 88         | 4 (4)     | 10 (9)    | 2 (2)     | 84 (74)   |

* The absolute number of cells (× 10⁶) for each surface phenotype is indicated in parentheses.
Figure 3. Histologic sections of thymi from kk-IL4 mice or nontransgenic littermate controls after formalin fixation and staining with hematoxylin and eosin. Low-power magnification ×2.5 of a kk-IL4 thymus (A) demonstrating markedly decreased size and cellularity and loss of a distinct cortical region compared with a nontransgenic littermate thymus (B). Higher-power magnification (×25 of the kk-IL4 thymus (C) showing the loss of a distinct cortical-medullary junction, and an overall loose-packing of cells characteristic of the normal medulla. In contrast, the thymus from a nontransgenic littermate (D) has a distinct cortical-medullary junction, with the cortical region densely packed with thymocytes; the medullary region is located in the upper right corner of the photomicrograph.

An increased proportion of lck-IL4 thymocytes expressed surface TCR-α/β as assessed by two-color staining with CD3 and pan-α/β TCR mAbs (Fig. 4 B), while the small numbers (<5%) of thymocytes bearing TCR-γ/δ did not differ significantly from that found in littermate controls (data not shown). To further characterize the lck-IL4 thymocyte populations that expressed surface TCR, three color staining for CD3, CD4, and CD8 was performed. This revealed that most CD4⁺CD8⁺ lck-IL4 thymocytes expressed detectable surface TCR, although a significant proportion of this population had lower amounts of surface TCR compared with control CD4⁺CD8⁺ thymocytes (Fig. 4 C, left). Thymocytes with this CD3⁺CD4⁺CD8⁺ surface phenotype normally first appear at the very end of fetal ontogeny (day 19) and include CD4⁺CD8⁺ cells destined to emigrate from the thymus (47). In contrast, there was no significant increase in the number of CD3⁻CD4⁻CD8⁺ thymocytes, a population which occurs earlier in fetal ontogeny (day 15), and is apparently the direct precursor of CD3⁺CD4⁺CD8⁺ thymocytes (48, 49). CD4⁺CD8⁻ thymocytes from transgenic and control mice exhibited similar levels of CD3 expression (data not shown). However, the proportion of CD4⁺CD8⁺ thymocytes that were CD3⁺ was strikingly increased in lck-IL4 mice compared with controls (Fig. 4 C, left and right). In agreement with previous work (36), the amount of CD3 staining on CD3⁺CD4⁺CD8⁺ thymocytes from either transgenic or control animals was relatively low compared with that found on most single-positive cells.

Reversal of Thymic Abnormalities in lck-IL4 Mice Treated with Anti-IL4 Antibody. To confirm that IL4 secretion was responsible for the phenotypic abnormalities of T-lineage cells in lck-IL4 mice, transgenic or control mice were treated for 1 mo with injections of either anti-IL4 mAb (11B11) or PBS. Transgenic mice that received anti-IL-4 mAb had striking increases in thymocyte number (Table 2) as well as partial normalization of thymic architecture (data not shown). The composition of thymocyte subsets defined by surface expression of CD4, CD8, and CD3 was also modified towards that found in normal mice, after treatment with anti-IL-4 but not PBS (Fig. 4 C, Table 2). There were no discernible effects on the thymi of control mice as a result of treatment with either anti-IL-4 or PBS. These results showed that the perturbation of thymic development observed in lck-IL4 mice was critically dependent on the secretion of IL-4.

Peripheral T Cells in lck-IL4 Mice. Phenotypic alterations in the peripheral T cell compartment were also evident in lck-IL4 mice. Most striking was the virtually complete absence of CD8⁺ T cells in the LN (Fig. 5 A), spleen, and
Figure 4. Two- and three-color immunofluorometric analysis of thymocytes from lck-IL-4 and nontransgenic littermate (LM) control mice. Thymocytes from 6-wk-old mice stained for (A) CD4 (GK1.5) vs. CD8 (104.21) and (B) TCR-α/β (H57-597) vs. CD3 (145-2C11). (C) Three-color analysis of thymocytes from 9-wk-old mice, after in vivo treatment with PBS or anti-IL-4 mAb (11B11), for CD4 (GK1.5) vs. CD3 (500A.2) on electronically gated cells positive for CD8 (104.21).

Figure 5. Two-color immunofluorescence analysis of LN cells from lck-IL-4 and nontransgenic littermate (LM) control mice for (A) CD4 (GK1.5) vs. CD8 (104.21) and (B) CD4 (GK1.5) vs. CD3 (500A.2).

**Table 3. Ig Isotype and IgG Subclass Levels (μg/ml ± SEM) in Adult lck-IL-4 (n = 12) and Littermate Control (n = 7) mice**

|        | IgM          | IgA          | IgE          | IgG1         | IgG2a         | IgG2b         | IgG3         |
|--------|--------------|--------------|--------------|--------------|---------------|---------------|--------------|
| lck-IL-4| 644 ± 436    | 1,510 ± 1,850| 2.7 ± 0.1    | 1,010 ± 806  | 268 ± 142*    | 395 ± 108     | 80 ± 60      |
| LM control | 384 ± 200    | 621 ± 484    | 2.5 ± 0.3    | 882 ± 898    | 142 ± 63      | 330 ± 94      | 35 ± 16      |

*p < 0.05 compared with LM control using the two-tailed Student’s t test.

**Thymocyte and Peripheral T Cell Activation Is Significantly Altered in lck-IL-4 Mice.** To determine if the lck-IL-4 transgene led to functional as well as phenotypic alterations of T-lineage cells, individual thymocytes and peripheral T cells were analyzed for activation-induced changes in [Ca^{2+}]. In all experiments, transgenic and control cell populations with analogous patterns of CD4 and CD8 surface expression were directly compared. As shown in Fig. 6, the calcium responses of transgenic thymocyte populations after stimulation were distinct from those observed in control cells: transgenic CD4^{+}CD8^{+} thymocytes had strikingly greater increases in mean [Ca^{2+}], compared with control CD4^{+}CD8^{+} thymocytes after treatment with anti-CD3 mAb (A), as well as Con A or anti-TCR-α/β mAb (data not shown). In contrast, the calcium response of single-positive thymocytes to anti-CD3 mAb treatment was dramatically lower than that of control populations (B and C). CD4^{+}CD8^{+} transgenic and control thymocytes both had low levels of response under these conditions (data not shown). When splenic CD4^{+} T cell populations were similarly analyzed, dramatically lower calcium responses were observed in transgenic cells compared with control cells after either anti-CD3 mAb or Con A treatment (D). Similar results were obtained using LN CD4^{+} T cells (data not shown). For all cell populations analyzed, the maximum percent of cells which gave a significant calcium response paralleled the peak mean [Ca^{2+}] achieved by these cells (see legend to Fig. 6). Transgenic peripheral CD8^{+} T
Figure 7. Proliferative response of lck-IL4 and littermate control spleen mononuclear cells to crosslinking with anti-CD3 or anti-TCR-α/β mAbs. After 60 h, cultures were pulsed for 12 h with [3H]thymidine. Counts were calculated as the mean ± SEM of triplicate determinations. Lck-IL4 cells are indicated by stippled bars, and littermate control cells are indicated by solid bars. The data have been normalized with respect to the percentage of CD3+ cells found in the spleen mononuclear cell preparations. In the experiment shown, 16% of lck-IL4 cells and 31% of littermate control cells were surface CD3+. Similar results were obtained in two additional experiments.

Figure 6. [Ca2+]i in stimulated thymocytes and splenic CD4+ T cells from lck-IL4 and littermate (LM) control mice. As described in Materials and Methods, cells were sequentially loaded with indo-1 dye, stained with PE-conjugated CD8 and FITC-conjugated CD4 mAbs, and analyzed for [Ca2+]i, using flow cytometry to gate on cell populations expressing surface CD4 and/or CD8. (A) CD4+CD8+, (B) CD4+CD8-, and (C) CD4+CD8+ thymocytes stimulated with anti-CD3 mAb (145-2C11). (D) Splenic CD4+ T cells stimulated with either anti-CD3 mAb (145-2C11) or Con A. Mean [Ca2+]i of all cells analyzed vs. time is plotted in each histogram. The maximum percentage of transgenic (TG) or littermate control (LM) cells which responded with elevations of [Ca2+]i by the end of the 8-min period as follows: (A) TG, 68%; LM, 55%; (B) TG, 12%; LM, 77%; (C) TG, 25%; LM, 74%; (D) anti-CD3; TG, 13%, LM, 52%; Con A; TG, 47%, LM, 75%.

Additional Abnormalities in lck-IL4 Mice. lck-IL4 mice were remarkably susceptible to parasitic infection. Conventionally housed transgenic mice, but not controls, invariably developed severe intestinal infection with the pinworm Syphacia obvelata (50). Megacolon, rectal prolapse, and cecal perforation were frequent findings. Most severely infected mice died between 6 and 12 wk of age. In contrast, infection of conventionally housed lck-IL4 mice with mouse hepatitis virus only rarely caused significant disease. Since IL4 has been shown to increase IgE and IgG1 isotype production by activated B cells in vitro (8), and to be directly involved in promoting IgE production in vivo during parasitic infection (11, 12), we determined the concentrations of these and, for comparison, other Ig isotypes in the circulation of pinworm-infected lck-IL4 mice and littermate controls (Table 3). There were no significant differences between transgenic and control mice in their plasma levels of IgM, IgA, IgE, IgG1, IgG2b, or IgG3. An unexpected finding was that IgG2a levels were significantly higher in infected lck-IL4 mice compared with controls. This observation may reflect the higher antigenic load experienced by lck-IL4 mice. These results, which suggested that B cell function was not grossly perturbed by the IL4 transgene, were consistent with the normal histologic appearance of lymphoid follicles and the normal numbers of peripheral B220+ B cells found in lck-IL4 mice (data not
shown). Since IL-4 has also been shown to act as a growth factor for mast cells (5), we histologically examined these transgenic mice for increased mast cell numbers using a Giemsa stain. However, we failed to find significant increases in mast cell abundance in any organs of *lk*-IL-4 mice, including the skin (data not shown).

Discussion

IL-4 has previously been shown to promote the growth of isolated thymocytes including fetal and adult CD4-CD8- cells, adult CD4+CD8- and CD4-CD8+ cells, but not CD4+CD8+ cells (15-21). In vitro studies using murine CD4-CD8- or human CD4-CD8-CD3-CD1+ thymocytes suggest that IL-4 preferentially promotes differentiation of double-negative or CD8+ y/8 T-lineage cells (16, 21). Consistent with this interpretation, incubation of isolated double-positive or single-positive TCR-α/β+ thymocytes with IL-4 does not significantly alter their surface expression of CD4, CD8, or CD3 (Lewis, D., unpublished observations). These results contrast with those obtained in our in vivo model, which demonstrate a profound influence of IL-4 on the abundance, surface phenotype, and TCR-mediated activation of thymocytes, particularly TCR-α/β+ cells at later stages of maturation, and on the ability of mature thymocytes to successfully colonize the periphery. We conclude that proper interactions between cytokines and the thymic microenvironment are crucially important in regulating multiple aspects of T cell development.

IL-4 expression by normal murine fetal thymocytes is highest at day 15 of gestation, when the predominant thymocyte population is CD4-CD8-, but rapidly declines by day 16, becoming undetectable from day 18 of gestation onward (13). This suggests a potential physiologic role for IL-4 in early thymic development. In preliminary experiments, we have examined the effects of the *lk*-IL-4 transgene on fetal thymic ontogeny at day 16.5-17 of gestation and have found no significant differences between transgenic and control thymocytes with respect to CD3, CD4, or CD8 surface expression (data not shown). Further, no significant differences were observed in the percentage of thymocytes bearing TCR-γ/δ, or in their surface expression of Thy-1, CD5, or CD45. IL-4 secretion by *lk*-IL-4 but not control thymocytes is detectable as early as day 18 of gestation (Table 1), and it is likely, based on the normal ontogeny of expression of the endogenous proximal *lk* promoter, that thymocytes express the *lk*-IL-4 transgene beginning as early as day 14 of gestation (reference 51; Lewis, D., and R. Perlmutter, unpublished observations). These findings argue that increased intrathymic expression of IL-4 has little discernible impact on T cell development before the appearance of double-positive thymocytes.

In contrast, the development of double-positive and TCR-α/β-bearing single-positive thymocytes is dramatically affected by in situ IL-4 production in adult mice. These results suggest that the progressive decrease in IL-4 expression by thymocytes which occurs during late fetal ontogeny may be critical for subsequent normal T cell development.

The thymi of *lk*-IL-4 mice lacked a clearly defined cortex, a region which in normal mice predominantly contains double-positive thymocytes (47). Cortical CD4+CD8+ thymocyte depletion is also a prominent feature of thymi from mice that have been physiologically stressed or treated with glucocorticoids. However, under these conditions the CD4+CD8- / CD4-CD8+ single-positive thymocyte ratio, which normally is 2-3:1, remains unchanged (52, 53). In contrast, in *lk*-IL-4 mice this ratio was typically 1:1 or less, reflecting an absolute increase in the number of CD4+CD8+ thymocytes. Hence, the alterations observed in thymic development in *lk*-IL-4 mice, which clearly depended on the secretion of IL-4 (Table 2, Exp. 2; Fig. 4 C), are unlikely to be simply the result of systemic stress.

The finding that CD4+CD8+ thymocytes had increased TCR surface expression in *lk*-IL-4 mice is particularly noteworthy, since no cytokine has previously been shown to mediate this effect. Although the mechanism by which IL-4 increases surface TCR expression on double-positive cells remains to be determined, the results of treatment of *lk*-IL-4 mice with anti-IL-4 mAb clearly show that this effect is dependent on the actual secretion of IL-4. Similar increases in surface TCR expression by double-positive thymocytes have also been observed after in vivo treatment of normal mice with anti-CD4 but not anti-CD8 mAb (54, 55), or when normal thymocytes are incubated in vitro in suspension but not as tissue fragments (55, 56). In both cases, a posttranslational mechanism, in which assembled CD3-TCR complexes are more efficiently transported from the endoplasmic reticulum to the cell surface, appears to be involved (55). These findings have led to the proposal that the thymic microenvironment may provide a signal through the CD4 molecule of CD4+CD8+ thymocytes which attenuates the surface expression of TCR by these cells (55). We have found that the inclusion of IL-4 in suspension cultures of normal thymocytes does not further augment surface TCR expression by double-positive thymocytes (Lewis, D., unpublished observations), suggesting that, like anti-CD4 mAb treatment, an intact thymic microenvironment is required for this IL-4-mediated effect. It remains to be determined whether an altered CD4-mediated signal in *lk*-IL-4 double-positive thymocytes is also responsible for their increased TCR expression, or whether thymi from *lk*-IL-4 mice have decreased surface expression of class II MHC, the presumed physiologic surface ligand for CD4 within the thymus (57).

An increasing body of evidence indicates that engagement of TCR-α/β on CD4+CD8+ thymocytes by self-MHC, presumably as part of a complex with self-antigen peptides, is critical both for the development of T cells with receptors capable of recognizing foreign antigen-self-MHC complexes (positive selection) as well as the deletion of T cells bearing TCR with potentially harmful self-reactivity (negative selection; for review see reference 58). The signals by which TCR engagement leads to either positive or negative selection of thymocytes remain poorly understood. In a model for negative selection using cultured fetal thymus lobes, CD4+CD8+ thymocytes which mobilize calcium after treat-
ment with anti-CD3 or anti-TCR-α/β mAbs are also eliminated by these mAbs during organ culture (59–61). This correlation between TCR-mediated calcium fluxes and in vitro deletion also provides a plausible explanation for the depletion of CD4+CD8- thymocytes observed in all lines of lck-IL4 mice. Lck-IL4 CD4+CD8- thymocytes, by virtue of their increased mobilization of [Ca2+]i; after TCR-CD3 complex engagement, might also be more prone to intrathymic deletion than normal double-positive thymocytes.

The expression of IL-4 intrathymically exerted different effects on mature CD4+CD8- as compared with CD4+CD8+ T-lineage cells. Only CD4+CD8- thymocytes were increased in absolute numbers in these thymi, while, in contrast, only CD4+ and not CD8+ T cells were found in the peripheral compartment. This suggests that CD4+CD8- thymocyte emigration was blocked in lck-IL4 mice, or that if emigration occurred, these cells failed to proliferate at peripheral sites. A significant, but less severe, decrease in the emigration of CD4+CD8- thymocytes might also account for the reduced numbers of peripheral lck-IL4 CD4+ T cells we observed. Although the mechanisms involved in the emigration of single-positive thymocytes into the circulation are poorly understood, our results suggest that cytokines such as IL-4 can differentially regulate this process in CD4+CD8- and CD4+CD8+ T lineage cells. The observation that IL-4 in vitro is significantly more effective in promoting the growth of CD4+CD8- compared with CD4+CD8- thymocytes (17) indicates that these two populations may differ intrinsically in their responses to IL-4 by other criteria as well.

Peripheral T cells as well as mature TCR-α/β-bearing single-positive thymocytes from lck-IL4 mice were markedly defective in their mobilization of calcium in response to anti-CD3 mAb or the mitogen, Con A (Fig. 6). However, lck-IL4 T cells appeared to proliferate as well as control cells in response to anti-CD3 or anti-TCR-α/β mAb (Fig. 7). Although thymidine incorporation by lck-IL4 splenocytes was lower than that by splenocytes from littermate controls, this decrease was proportional to the lower percentage of peripheral T cells found in this transgenic population (see legend to Fig. 7). The mechanism(s) responsible for this relatively selective defect in proximal signal transduction by mature lck-IL4 T-lineage cells remain to be defined. T cell proliferation after activation via the TCR-CD3 complex has previously been shown to be dependent on the interaction of IL-2 with its specific high-affinity receptor (62), suggesting that this interaction occurred normally in lck-IL4 peripheral T cells. This interpretation is supported by the fact that IL-2 mRNA accumulation in lck-IL4 cells activated with either anti-CD3 mAb, Con A, or ionomycin and PMA was at least equal to that observed in littermate controls (data not shown). Therefore, it is possible that lck-IL4 and peripheral T cells may be capable of IL-2 production by a calcium-independent pathway. Since a calcium-independent pathway for IL-2 production has previously only been described in murine T cell hybridoma line variants or mutants deficient in CD3-η chains (63, 64), it will be of interest to confirm that TCR-mediated proliferation of mature lck-IL4 T-lineage cells is calcium independent and, if so, whether these cells have decreased CD3-η expression as well as reduced activation-induced phosphoinositide hydrolysis. Alternatively, mature lck-IL4 thymocytes and T cells may be more susceptible to inhibition of TCR-mediated calcium mobilization by anti-CD4 or -CD8 mAb, which were used to identify cell subsets in these assays, than are control cells. Such inhibition of TCR-mediated calcium mobilization by anti-CD4 mAb has previously been observed in certain T cell clones (65).

An unexpected finding in lck-IL4 mice was their susceptibility to severe infection by the pinworm Syphacia obvelata. Previous adoptive transfer studies with nude mice have indicated that T-lineage cells may be critical for the control of this pathogen (50). In other murine models, CD4+ T cells have also been shown to be important for the control of other parasitic infections, including Nippostrongylus and Leishmania (66, 67). Therefore, it is possible that the generally low numbers of peripheral lck-IL4 T cells, as well as their apparent functional defects, could both contribute to the vulnerability of lck-IL4 mice to parasitic infection. It remains to be shown that lck-IL4 T cells have defective antigen-specific responses in vitro or in vivo.

While preparing this manuscript we became aware of data by Tepper et al. (68) showing that an IL-4 transgene under the control of the μ H chain enhancer results in the increased expression of IL-4 by T+ as well as B-lineage cells. These mice demonstrate most of the phenotypic alterations in T-lineage cells we have observed in lck-IL4 mice, confirming that these results are attributable to the IL-4 gene product itself. However μ H chain enhancer-IL4 transgenic mice differ from lck-IL4 mice in that their serum levels of IgG1 and IgE isoforms are increased, and their skin and eyes are infiltrated with large numbers of mast cells. Our failure to observe these effects on non-T lineage cells in lck-IL4 mice, despite their constitutive intrathymic production of significant amounts of IL-4, indicates that this cytokine acts locally rather than systemically, even when it is overexpressed in vivo. A soluble form of the IL-4R has recently been identified in the circulation of mice (69, 70). Soluble IL-4R could potentially bind excess IL-4 produced in tissues and prevent the occurrence of systemic effects. Recent studies by Maliszewski et al. (45) have shown that soluble IL-4R can inhibit IL-4-mediated effects in vitro. Our results suggest that mechanisms of this type, limiting the effects of IL-4 at a distance, are of considerable importance. In the absence of such regulation, peripheral IL-4 production in response to inflammatory stimuli could potentially compromise intrathymic T cell development. Hence, it will be of interest to determine whether the levels of circulating IL-4-IL-4R complexes are increased in lck-IL4 mice, and whether the production of soluble receptor is upregulated in response to the constitutive synthesis of IL-4 intrathymically.
We thank Judith Westall for technical assistance with the IL-4 bioassay; Janice Hall, Patsy McEnany, and Geri Pingul for performing flow cytometric analysis; and Barbara Loveth for preparation of this manuscript.

This work was supported by grant AI/HD 26940 from the National Institutes of Health and by the Howard Hughes Medical Institute.

Address correspondence to Dr. David B. Lewis, Division of Immunology, Department of Pediatrics, Children's Hospital and Medical Center, P.O. Box C-5371, Seattle, WA 98105.

Received for publication 15 August 1990 and in revised form 5 October 1990.

References

1. Paul, W.E., and J. Ohara. 1987. B-cell stimulatory factor-1/interleukin 4. Annu. Rev. Immunol. 5:429.
2. Howard, M.J., Farrar, M. Hilfiker, B. Johnson, K. Takatsu, T. Hamaoka, and W.E. Paul. 1982. Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J. Exp. Med. 155:914.
3. Mosmann, T.R., M.W. Bond, R.L. Coffman, J. Ohara, and W.E. Paul. 1986. T-cell and mast cell lines respond to B-cell stimulatory factor 1. Proc. Natl. Acad. Sci. USA. 83:5654.
4. Fernandez-Botran, R., P.H. Kramer, T. Diamanstein, J.W. Uhr, and E.S. Vitetta. 1986. B cell-stimulatory factor 1 (BSF-1) promotes growth of helper T cell lines. J. Exp. Med. 164:580.
5. Brown, M.A., J.H. Pierce, C.J. Watson, J. Falco, J.N. Igle, and W.E. Paul. 1987. B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells. Cell. 50:809.
6. Roehm, N.W., H.J. Leibson, A. Zlotnik, J. Kappler, P. Marrack, and J.C. Cambier. 1984. Interleukin-induced increase in If expression by normal mouse B cells. J. Exp. Med. 160:679.
7. Snapper, C.M., and W.E. Paul. 1987. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science (Wash. DC). 236:944.
8. Widmer, M.B., and K.H. Grabstein. 1987. Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor. Nature (Lond.). 326:795.
9. Paliard, X., R. de Waal Malefijit, J.E. de Vries, and H. Spits. 1988. Interleukin-4 mediates CD8 induction on human CD4+ T-cell clones. Nature (Lond.). 335:642.
10. Finkelman, F.D., J.F. Urban, C.M. Snapper, J. Ohara, and W.E. Paul. 1986. Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. Proc. Natl. Acad. Sci. USA. 83:9675.
11. Carding, S.R., E.J. Jenkinson, R. Kingdom, A.C. Hayday, K. Bottomly, and J.T. Owen. 1989. Developmental control of lymphokine gene expression in fetal thymocytes during T-cell ontogeny. Proc. Natl. Acad. Sci. USA. 86:3342.
12. Tentori, I., D.M. Pardoll, J.C. Zuniga, J. Hu-Li, W.E. Paul, J.A. Bluestone, and A.M. Kruisbeek. 1988. Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3. J. Immunol. 140:1089.
13. Takashi, T., A.D. Steinberg, C.H. June, and W.C. Gause. 1987. Responsiveness of fetal and adult CD4+ , CD8- thymocytes to T cell activation. J. Immunol. 142:2641.
14. Takashi, T., A.D. Steinberg, C.H. June, and W.C. Gause. 1987. Recombinant interleukin 4/BSF-1 promotes growth and differentiation of intrathymic T cell precursors from fetal mice in vitro. EMBO (Eur. Mol. Biol. Organ.) J. 6:91.
15. Zlotnik, A., J. Ransom, G. Frank, M. Fischer, and M. Howard. 1987. Interleukin 4 is a growth factor for activated thymocytes: possible role in T-cell ontogeny. Proc. Natl. Acad. Sci. USA. 84:3856.
16. Suda, T., R. Murray, M. Fischer, T. Yokota, and A. Zlotnik. 1990. Tumor necrosis factor-α and P40 induce day 15 murine fetal thymocyte proliferation in combination with IL-2. J. Immunol. 144:1783.
17. Suda, T., R. Murray, C. Guidos, and A. Zlotnik. 1990. Growth-promoting activity of IL-1α in combination with IL2, IL-4, or IL-7 on murine thymocytes: differential effects on CD4/CD8 subsets on CD3+/CD3- double-negative thymocytes. J. Immunol. 144:3039.
18. Carding, S.R., and K. Bottomly. 1988. IL-4 (B cell stimulatory factor 1) exhibits thymocyte growth factor activity in the presence of IL2. J. Immunol. 140:1519.
19. Barcena, A.M., L. Toribio, L. Pezzi, and C. Martinez-A. 1990. A role for interleukin 4 in the differentiation of mature T cell receptor γδ+ cells from human intrathymic T cell precursors. J. Exp. Med. 172:439.
20. Noma, Y., P. Sideras, T. Naito, S. Bergstedt-Lindquist, C. Azuma, E. Severinson, T. Tanabe, T. Kinashi, F. Matsuda, Y. Yaito, and T. Honjo. 1986. Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter. Nature (Lond.). 319:640.
21. Maniatis, T., E.F. Fristch, and J.Sambrook. 1982. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
22. Gavirin, A.M., S. Pawar, J.D. Martih, and R.M. Perlmutter. 1988. Structure of the murine k5 gene and its rearrangement in a murine lymphoma cell line. Mol. Cell. Biol. 8:3058.
23. Gavin, A.M., K.M. Abraham, K.A. Forbush, A.G. Farr, B.L. Davison, and R.M. Perlmutter. 1990. Disruption of thymocyte development and lymphomagenesis induced by SV40 T-antigen. International Immunology. 2:173.
24. Seeburg, P.H. 1982. The human growth hormone gene family: nucleotide sequences show recent divergence and predict a new polypeptide hormone. DNA (NY). 1:239.
27. Brinster, R.L., H.Y. Chen, M.E. Trumbauer, M.K. Yagle, and R.D. Palmiter. 1985. Factors affecting the efficiency of introducing foreign DNA into mice by microinjection of eggs. Proc. Natl. Acad. Sci. USA. 82:4438.

28. Glinis, V., R. Crkvenjakov, and C. Byus. 1974. Ribonucleic acid isolated by cesium chloride centrifugation. Biochemistry. 13:2633.

29. Lewis, D.B., A. Larsen, and C.B. Wilson. 1986. Reduced interferon-gamma mRNA levels in human neonates: evidence for an intrinsic T cell deficiency independent of other genes involved in T cell activation. J. Exp. Med. 163:1018.

30. Lewis, C.B., K.S. Prickett, A. Larsen, K. Grabstein, M. Weaver, and C.B. Wilson. 1988. Restricted production of interleukin 4 by activated human T cells. Proc. Natl. Acad. Sci. USA. 85:9743.

31. Feinberg, A., and B. Vogelstein. 1983. A technique for radio-labeling DNA restriction endonuclease fragments to high specificity activity. Anal. Biochem. 132:6.

32. Boyum, A. 1974. Separation of blood leucocytes, granulocytes, and lymphocytes. Tissue Antigens. 4:269.

33. Mishell, B.B., and S.M. Shiigi, editors. 1980. Selected Methods in Cellular Immunology. W.H. Freeman and Co. Publishers, New York. 3–27.

34. Hu-Li, J., J. Ohara, C. Watson, W. Tsang, and W.E. Paul. 1989. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT-4R) and of an IL-2 hyperresponsive mutant of that line (CT-4S). J. Immunol. 142:800.

35. Ohara, J., and W.E. Paul. 1985. Production of a monoclonal antibody and molecular characterization of B cell stimulatory factor-1. Nature (Lond.). 315:333.

36. Havran, W.L., M. Poenie, J. Kimura, R. Tsien, A. Weiss, and J.P. Allison. 1987. Expression and function of the CD3 antigen receptor on murine CD4+8+ thymocytes. Nature (Lond.). 330:170.

37. Leo, O., M. Foo, D.H. Sachs, L.E. Samelson, and J.A. Bluestone. 1987. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA. 84:1374.

38. Kubo, R.T., W. Born, J.W. Kappler, P. Marrack, and M. Fowlkes. 1989. Characterization of a monoclonal antibody which detects all murine αβ T cell receptors. J. Immunol. 142:2736.

39. Dialynas, D.P., D.R. Wilde, P. Marrack, A. Pierres, K.A. Wall, W. Havran, G. Otten, M.R. Loken, M. Pierres, J. Kappler, and F.W. Fisch. 1983. Characterization of the murine antigenic determinant, designated L3T4α, recognized by monoclonal antibody GKL5: expression of L3T4α by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol. Rev. 74:29.

40. Ledbetter, J.A., and L.A. Herzenberg. 1979. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol. Rev. 47:63.

41. Wilson, C.B., J. Westall, L. Johnston, D.B. Lewis, S.K. Dower, and A.R. Alpert. 1986. Decreased production of interferongamma by human neonatal cells. J. Clin. Invest. 77:860.

42. Grynkiewicz, G., M. Poenie, and R.Y. Tsien. 1985. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:3440.

43. Rabinovich, P.S., C.H. June, A. Grossman, and J.A. Ledbetter. 1986. Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of Indo-1 and immunofluorescence with flow cytometry. J. Immunol. 137:952.

44. Grossman, A., J.A. Ledbetter, and P.S. Rabinovich. 1990. Aging-related deficiency in intracellular calcium response to anti-CD3 or Concanavalin A in murine T-cell subsets. J. Gerontol. 45:B81.

45. Maliszewski, C.R., T.A. Sato, T. Vanden Bos, S. Waugh, S.K. Dower, J. Slack, M.P. Beckmann, and K.H. Grabstein. 1990. Cytokine receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-1 and IL-4 induced B cell activities in vitro. J. Immunol. 144:3028.

46. Brinster, R.L., J.M. Allen, R.R. Behringer, R.E. Gelinas, and R.D. Palmiter. 1988. Introns increase transcriptional efficiency in transgenic mice. Proc. Natl. Acad. Sci. USA. 85:836.

47. Fowlkes, B.J., and D.M. Pollow. 1989. Molecular and cellular events of T cell development. Adv. Immunol. 44:207.

48. Nikolizic, J., and M.J. Bevan. 1988. Thymocytes expressing CD8 differentiate into CD4+ cells following intrathymic injection. Proc. Natl. Acad. Sci. USA. 85:8633.

49. Guidos, C.J., I.L. Weissman, and B. Adkins. 1989. Intrathymic maturation of murine T lymphocytes from CD8+ precursors. Proc. Natl. Acad. Sci. USA. 86:7542.

50. Jacobson, R.J., and N.D. Reed. 1974. The thymus dependency of resistance to pinworm infection in mice. J. Parasitol. 60:976.

51. Pernalmus, R.M., J.D. Marsh, D.B. Lewis, R. Peet, S.F. Ziegler, and C.B. Wilson. 1988. Structure and expression of Iκκ transcripts in human lymphoid cells. J. Cell. Biochem. 38:117.

52. Blomgren, H., and B. Andersson. 1971. Characteristics of the immunocompetent cells in the mouse thymus: cell populations changes during cortisone-induced atrophy and subsequent regeneration. Cell. Immunol. 1:545.

53. Scollay, R., P. Barlett, and K. Shortman. 1984. T cell development in the adult murine thymus: changes in the expression of the surface antigens Ly2, L3T4, and B2A2 during development from early precursor cells to emigrants. Immunol. Rev. 82:79.

54. McCarthy, S.A., A.M. Krusiebeek, I.K. Uppenkamp, S.O. Sharrow, and A. Singer. 1988. Engagement of the CD4 molecule influences cell surface expression of the T-cell receptor on thymocytes. Nature (Lond.). 336:76.

55. Bonifacino, J.S., S.A. McCarthy, J.E. Maguire, T. Nakayama, D.S. Singer, R.D. Klausner, and A. Singer. 1990. Novel post-translational regulation of TCR expression in CD4+CD8+ thymocytes influenced by CD4. Nature (Lond.). 344:247.

56. White, J., A. Herman, A.M. Pallen, R. Kubo, J.W. Kappler, and P. Marrack. 1989. The V2 specificity superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion of neonatal mice. Cell. 56:27.

57. Robey, E., and R. Axel. 1990. CD4: collaborator in immune recognition and HIV infection. Cell. 60:697.

58. Blackman, M., J. Kappler, and P. Marrack. 1990. The role of the T cell receptor in positive and negative selection of developing T cells. Science (Wash. DC). 248:1335.

59. Smith, C.A., G.T. Williams, R. Kingdon, E.J. Jenkinson, and J.T. Owen. 1989. Antibodies to CD3/Fc cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature (Lond.). 337:181.

60. Finkel, T.H., J.C. Cambier, R.T. Kubo, W.K. Born, P. Marrack, and J.W. Kappler. 1989. The thymus has two functionally distinct populations of immature αβ T cells: one population is deleted by ligation of αβTCR. Cell. 58:1047.

61. Finkel, T.H., P. Marrack, J.W. Kappler, R.T. Kubo, and J.C. Cambier. 1989. αβ T cell receptor and CD3 transduce different signals in immature T cells. J. Immunol. 142:3006.

62. Weiss, A., J. Imboden, K. Hardy, B. Manger, C. Terhorst, and J. Stobo. 1986. The role of the T3/antigen receptor com-
plex in T-cell activation. Annu. Rev. Immunol. 4:593.

63. Sussman, J.J., M. Mercep, T. Saito, R.N. Germain, E. Bonvini, and J.D. Ashwell. 1988. Dissociation of phosphoinositide hydrolysis and Ca2+ fluxes from the biological responses of a T-cell hybridoma. Nature (Lond.). 334:625.

64. Mercep, M., J.S. Bonifacino, P. Garcia-Morales, L.E. Samelson, R.D. Klausner, and J.D. Ashwell. 1988. T Cell CD3-ζ heterodimer expression and coupling to phosphoinositide hydrolysis. Science (Wash. DC). 242:571.

65. Tamura, T., J. Mizuguchi, and H. Nariuchi. 1990. Regulatory role of CD4/L3T4 molecules in IL-2 production by affecting intracellular Ca2+ concentration of T cell clone stimulation with soluble anti-CD3. J. Immunol. 145:78.

66. Katona, I.M., J.F. Urban, Jr., and F.D. Finkelman. 1988. The role of L3T4+ and Lyt-2+ T cells in the IgE response and immunity to Nippostrongylus brasiliensis. J. Immunol. 140:3206.

67. Muller, I., J.A. Garcia-Sanz, R. Titus, R. Behn, and J. Louis. 1989. Analysis of the cellular parameters of the immune responses contributing to resistance and susceptibility of mice to infection with the intracellular parasite Leishmania major. Immunol. Rev. 112:95.

68. Tepper, R.I., D.A. Levinson, B.Z. Sanger, J. Campos-Torres, A.K. Abbas, and P. Leder. 1990. IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell. 62:457.

69. Mosley, B., M.P. Beckmann, C.J. March, R.L. Idzerda, S.D. Gimpel, T. Vanden Bos, D. Friend, A. Alpert, D. Anderson, J. Jackson, J.M. Wignall, C. Smith, B. Gallis, J.E. Sims, D. Urdal, M.B. Widmer, D. Cosman, and L.S. Park. 1989. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell. 59:335.

70. Fernandez-Botran, R., and E.S. Vitetta. 1990. A soluble, high-affinity, interleukin-4 binding protein is present in the biological fluids of mice. Proc. Natl. Acad. Sci. USA. 87:4206.